1.古汉益康源片抗衰老的机制研究（主持），北京紫福生物科技有限公司，2022-2024

2.国内外自我药疗疾病谱对照研究（主持），中国非处方药物协会，2019-2020

3. FDP对中枢神经系统的观察研究（主持），德清东立富宝有限公司，2018-2019

4. FCN411治疗NSCLC的研究（主持），上海复星医药奥鸿药业有限公司，2016-2018

5.人参皂甙提取物SP18抗肿瘤研究（主持），首都中医药专项，2015-2016

6. NRG1/HER3通路激活致乳腺癌曲妥珠单抗原发耐药的分子机制（81301912，第二），国家自然科学基金，2014-2016

7. 中西非处方药物口服制剂联合使用的原则和注意事项（主持），北京市自我药疗科技传播中心，2013-2014

8. 卡培他滨在胃癌患者体内的药物代谢研究（主持），北京市卫生局，2011-2013

近5年发表的主要SCI论文：

1.Ling Li, Anqi Lou, Junxian Yu(余俊先)*. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature. Ann Palliat Med. 2021;10(7): 8460-8466.

2.Chunna Liu, Chunhua Shao, Qi Du, Chaoran He, Xinyuan Sun, Anqi Lou, Zhijie Ma*, Junxian Yu (余俊先)*. Mechanism and effects of fructose diphosphate on anti-hypoxia fatigue and learning memory ability. Can J Physiol Pharmacol. 2020; 98(10):733-740.

3.Lingye Zhang, Juan Liu, Fandong Meng, Yingying Guan, Yongjun Wang, Shengtao Zhu, Yaqiong Liu, Qing Xie, Junxian Yu (余俊先)*, Shutian Zhang*. Pharmacokinetics of Bismuth following Oral Administration of Wei Bi Mei in Healthy Chinese Volunteers. Evid Based Complement Alternat Med. 2020: 2679034.  doi: 10.1155/2020/ 2679034. eCollection 2020.

4.Yingjie Ma, Junxian Yu (余俊先) , Qin Li , Qiang Su, Bangwei Cao*.  Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy. Biosci Biotechnol Biochem. 2020; 84(4): 743-756.

5.Wu J, Wang J, Su Q, Ding W, Li T, Yu J (余俊先)*, Cao B*. Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis. Onco Targets Ther. 2018; 11: 2685-2698.                          

6.Geng F, Yin H, Li Z, Li Q, He C, Wang Z, Yu J (余俊先)*. Quantitative analysis of necrostatin-1, a necroptosis inhibitor by LC-MS/MS and the study of its pharmacokinetics and bioavailability. Biomed Pharmacother. 2017; 95:1479-1485.                      

7.Geng F, Wang Z, Yin H, Yu J (余俊先)*, Cao B*. Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biother Radiopharm. 2017; 32(5):149-160.                           

8.Li Z, Li Q, Wu J, Wang M, Yu J (余俊先)*. Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do? Molecules. 2016; 21(10).                             

9.Yu J (余俊先), Liu C, Li Z, Zhang C, Wang Z, Liu X. Inhibitory effects and mechanism of 25-OH-PPD on glomerular mesangial cell proliferation induced by high glucose. Environ Toxicol Pharmacol. 2016; 44:93-98.                                                         

10.Yu J (余俊先), Li Z, Wang W, Zhang Y, Li D, Liu Y, Shen S, Zhang R. Anticancer 20(R)-dammarane- 3,12,20,25- tetrol-loaded polymericmicelles: Preparation, quantification and pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1022: 13-20.